When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

MLA

Pulley, Jill M., et al. “When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.” Assay and Drug Development Technologies, vol. 15, no. 8, Dec. 2017, pp. 354–61. EBSCOhost, https://doi.org/10.1089/adt.2017.821.

APA

Pulley, J. M., Jerome, R. N., Zaleski, N. M., Shirey-Rice, J. K., Pruijssers, A. J., Lavieri, R. R., Chettiar, S. N., Naylor, H. M., Aronoff, D. M., Edwards, D. A., Niswender, C. M., Dugan, L. L., Crofford, L. J., Bernard, G. R., & Holroyd, K. J. (2017). When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. Assay and Drug Development Technologies, 15(8), 354–361. https://doi.org/10.1089/adt.2017.821

Chicago

Pulley, Jill M, Rebecca N Jerome, Nicole M Zaleski, Jana K Shirey-Rice, Andrea J Pruijssers, Robert R Lavieri, Somsundaram N Chettiar, et al. 2017. “When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.” Assay and Drug Development Technologies 15 (8): 354–61. doi:10.1089/adt.2017.821.